期刊
REGENERATIVE MEDICINE
卷 10, 期 7, 页码 863-883出版社
FUTURE MEDICINE LTD
DOI: 10.2217/rme.15.52
关键词
3D bioprinting; additive manufacturing; ATMP; autologous; combination; customization; EMA; personalized; regulation; US FDA; validation
资金
- EPSRC
- Engineering and Physical Sciences Research Council [EP/K037099/1, EP/H028277/1] Funding Source: researchfish
- EPSRC [EP/K037099/1, EP/H028277/1] Funding Source: UKRI
Computer-aided 3D printing approaches to the industrial production of customized 3D functional living constructs for restoration of tissue and organ function face significant regulatory challenges. Using the manufacture of a customized, 3D-bioprinted nasal implant as a well-informed but hypothetical exemplar, we examine how these products might be regulated. Existing EU and USA regulatory frameworks do not account for the differences between 3D printing and conventional manufacturing methods or the ability to create individual customized products using mechanized rather than craft approaches. Already subject to extensive regulatory control, issues related to control of the computer-aided design to manufacture process and the associated software system chain present additional scientific and regulatory challenges for manufacturers of these complex 3D-bioprinted advanced combination products.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据